Results 91 to 100 of about 231,349 (305)

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma

, 2017
The treatment landscape of advanced melanoma has changed significantly following the discovery and marketing authorisation of immune checkpoints inhibitors. Ipilimumab (anti-CTLA-4) was the first one to be approved, and it.
Andrzej Mackiewicz, Jacek Mackiewicz
core   +1 more source

Commentary: The checkpoint before checkpoint inhibitors [PDF]

The Journal of Thoracic and Cardiovascular Surgery, 2020
William A, Blessing, Yolonda L, Colson
openaire   +2 more sources

Checking up on checkpoint inhibitors [PDF]

Blood, 2017
In this issue of Blood , Haverkos et al present timely and compelling data revealing both the opportunity and serious hazards incurred with the use of programmed death 1 (PD-1) pathway blockade after allogeneic hematopoietic cell transplant (allo-HCT) in relapsed lymphoma patients ...
Richard F. Little, Howard Streicher
openaire   +2 more sources

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Research Progress of Immune Checkpoint Inhibitors in Colorectal Cancer

Zhongliu Fangzhi Yanjiu, 2020
Tumor immunity is a new line of research for the treatment of patients with solid tumors, and negative regulators of the immune system called immune checkpoints play a key role in limiting antitumor immunologic responses.
ZHUANG Yuwen, SHEN Junyi, LIU Shenlin, CAI Hui   +3 more
doaj   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Checkpoint Inhibitors: Applications for Autoimmunity

Current Allergy and Asthma Reports, 2017
To limit excessive T cell-mediated inflammatory responses, the immune system has a milieu of inhibitory receptors, called immune checkpoints. Cancer cells have evolved to seize those inhibitory pathways and to prevent T cell-mediated killing of tumor cells.
Anna S, Tocheva, Adam, Mor
openaire   +3 more sources

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Nephrotic syndrome with acute kidney injury due to combination therapy of immune checkpoint inhibitors: a case report and review of the literature

BMC Nephrology
Background Recent studies have focused on immune checkpoint inhibitors. Renal complications associated with the use of immune checkpoint inhibitors are uncommon compared with other immune-related adverse events.
Ryosuke Saiki, Kan Katayama, Haruko Saiki, Ayumi Fukumori, Kayo Tsujimoto, Masahiro Yamawaki, Fumika Tanaka, Daisuke Takahashi, Keiko Oda, Yasuo Suzuki, Tomohiro Murata, Kaoru Dohi   +11 more
doaj   +1 more source